These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11312688)

  • 21. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
    Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
    J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
    Tsai SW; Sun Y; Williams LE; Raubitschek AA; Wu AM; Shively JE
    Bioconjug Chem; 2000; 11(3):327-34. PubMed ID: 10821648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of metal-chelating polymers (MCPs) for 111In complexed via the streptavidin-biotin system to trastuzumab Fab fragments on tumor and normal tissue distribution in mice.
    Boyle AJ; Liu P; Lu Y; Weinrich D; Scollard DA; Ngo Njock Mbong G; Winnik MA; Reilly RM
    Pharm Res; 2013 Jan; 30(1):104-16. PubMed ID: 22907419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
    DeNardo SJ; Zhong GR; Salako Q; Li M; DeNardo GL; Meares CF
    J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
    Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biodistribution of anti-CEA F(ab')2 fragments conjugated with chelating polymers: influence of conjugate electron charge on tumor uptake and blood clearance.
    Slinkin MA; Curtet C; Faivre-Chauvet A; Sai-Maurel C; Gestin JF; Torchilin VP; Chatal JF
    Nucl Med Biol; 1993 May; 20(4):443-52. PubMed ID: 8504286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide linkers lead to modification of liver metabolism and improved tumor targeting of copper-67-labeled antibody fragments.
    Novak-Hofer I; Zimmermann K; Schubiger PA
    Cancer Biother Radiopharm; 2001 Dec; 16(6):469-81. PubMed ID: 11789024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels.
    Arano Y; Fujioka Y; Akizawa H; Ono M; Uehara T; Wakisaka K; Nakayama M; Sakahara H; Konishi J; Saji H
    Cancer Res; 1999 Jan; 59(1):128-34. PubMed ID: 9892197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu.
    Mohsin H; Jia F; Sivaguru G; Hudson MJ; Shelton TD; Hoffman TJ; Cutler CS; Ketring AR; Athey PS; Simón J; Frank RK; Jurisson SS; Lewis MR
    Bioconjug Chem; 2006; 17(2):485-92. PubMed ID: 16536481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.
    Smith-Jones PM; Pandit-Taskar N; Cao W; O'Donoghue J; Philips MD; Carrasquillo J; Konner JA; Old LJ; Larson SM
    Nucl Med Biol; 2008 Apr; 35(3):343-51. PubMed ID: 18355690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment.
    Kobayashi H; Yoo TM; Kim IS; Kim MK; Le N; Webber KO; Pastan I; Paik CH; Eckelman WC; Carrasquillo JA
    Cancer Res; 1996 Aug; 56(16):3788-95. PubMed ID: 8706025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.
    Li M; Meares CF; Zhong GR; Miers L; Xiong CY; DeNardo SJ
    Bioconjug Chem; 1994; 5(2):101-4. PubMed ID: 8031871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy.
    Junghans RP; Dobbs D; Brechbiel MW; Mirzadeh S; Raubitschek AA; Gansow OA; Waldmann TA
    Cancer Res; 1993 Dec; 53(23):5683-9. PubMed ID: 8242624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl.
    Grünberg J; Jeger S; Sarko D; Dennler P; Zimmermann K; Mier W; Schibli R
    PLoS One; 2013; 8(4):e60350. PubMed ID: 23565233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biodistribution and tumor localization of 111In-labeled unmodified and modified F(ab')2 fragments of human monoclonal IgM (16.88) in a nude mouse model.
    Quadri SM; Siddiqui A; Klein JL; Vriesendorp HM
    Nucl Med Biol; 1995 May; 22(4):413-23. PubMed ID: 7550017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl- or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions.
    Li L; Tsai SW; Anderson AL; Keire DA; Raubitschek AA; Shively JE
    Bioconjug Chem; 2002; 13(1):110-5. PubMed ID: 11792185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
    Wang Z; Mårtensson L; Nilsson R; Bendahl PO; Lindgren L; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7171s-7177s. PubMed ID: 16203818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.